GSK plc (GSK) vs State Street SPDR S&P 500 ETF (SPY)
Over the past 10 years, GSK lagged SPY — 6.47% vs 15.36% annualized total return (price plus dividends).
A side-by-side comparison of GSK plc and State Street SPDR S&P 500 ETF across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 11, 2026. Differences are shown without an overall score or investment verdict.
Total return — GSK vs SPY
growth of $100 · dividends reinvested · last 10yMetrics side by side
Did GSK beat SPY?
Over the past 10 years, GSK lagged SPY — 6.47% vs 15.36% annualized total return (price plus dividends).
Total return (annualized)
| Metric | GSK | SPY |
|---|---|---|
| Total return (1Y) | 42.96% | 22.54% |
| Total return CAGR (3Y) | 18.73% | 21.63% |
| Total return CAGR (5Y) | 9.56% | 13.32% |
| Total return CAGR (10Y) | 6.47% | 15.36% |
SPY is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has GSK beaten SPY?
- Over the past 10 years, GSK lagged SPY — 6.47% vs 15.36% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 11, 2026.